{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"29.9","upperLimit":"80.2","value":"56.3"},{"groupId":"OG001","lowerLimit":"4.66","upperLimit":"50.8","value":"21.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"id":"OG000","title":"Follicular/Phase II (Efficacy)"},{"id":"OG001","title":"Mantle Cell Lymphoma/Phase II (Efficacy)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"From first response assessment (day 22 to 28 of Cycle 2) to last response assessment on day 22-28 in even-numbered cycles","title":"Phase II: Overall Response Rate (CR+PR)","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}